The full version of this counterfeiting feature can be read in the July issue of our digital magazine: http://www.pharmtech.com/ptedigital0710
The problem of counterfeit medicines was first addressed at an international level in 1985, when a conference of experts recommended
that the World Health Organization (WHO), together with other international and non-governmental organisations, should study
the feasibility of setting up a clearing house to collect data and to inform governments about the nature and extent of counterfeiting.
Since then, however, the problem has only escalated. According to the WHO, the magnitude of the issue is difficult to assess
because of the variety of information sources available.1 Additionally, the WHO stresses that counterfeiters are extremely flexible and can change their methods from day to day,
so the results of a study may already be out of date the day they are released.
Jason Hosking/Getty Images
|
However, the statistics that are available show unsettling results. For example, compared with 2005, seizures of counterfeit
medicines at the EU border increased by 380% in 2007.2 Meanwhile, research commissioned by Aegate revealed that 5% of consumers across five European countries suspect they may
have received a counterfeit prescription drug.3 The research adds that the majority of consumers believe that the trade in counterfeit medicines is largely the responsibility
of the manufacturer.
Fortunately, the threat of counterfeits has prompted the development of a number of anti-counterfeiting solutions, from simple
holograms and watermarks, to sophisticated barcodes that enable track and trace, tagged packages, and even technologies that
can be applied directly to individual tablets. But which solution is most widely used by the pharma industry?
Figure 1
|
To get a better idea, PTE conducted a survey4 of industry executives and found that, although barcoding and tamper-evident packaging was the most popular solution in
use amongst those surveyed, astonishingly, the majority of respondents (27%) admitted that their company had yet to instate
an anti-counterfeiting solution (Figure 1).
Products can never be made completely secure against counterfeiting; however, counterfeiters will always target medicines
that are easiest to copy. In the EU, companies that have yet to implement a solution are going to have to move quickly in
light of the significant threat that counterfeiting presents as well as amendments that are being made to the current EU anti-counterfeiting
directive; one of which mandates safety features, such as seals or serial numbers, for certain medicines.5
Speaking to a variety of industry leaders, PTE examines some of the trends in anti-counterfeiting technologies, as well as the innovative solutions being used by the industry.
References
1. WHO, Medicines: counterfeit medicines, Fact sheet N°275 (2010).
http://www.who.int/
2. European Commission, Counterfeit Medicines (2010). http://ec.europa.eu/
3. Aegate, Medicines top counterfeit concern list in Europe — consumers call for tougher safety measures (2009).
http://www.aegate.com/
4.
http://www.pharmtech.com/counterfeitpoll
5. European Parliament, Fake medicines: MEPs want to target online sales (2010).
http://www.europarl.europa.eu/
